Cancer drugs are the single biggest battlefield in pharma — a market worth over $220 billion a year, and the best-selling drug on Earth is a cancer drug. The way we attack tumors has evolved through four eras: from "poison the whole body" to "hit one precise target," then "take the brakes off the immune system and let it fight," and most recently the "guided missile" that delivers a toxin straight into the cancer cell. This is the story of a hunt that isn't over yet.
Bispecific and ADC wins lift oncology; Keytruda patent loss and a trial miss weigh
▲
Bispecific antibody combo scores first frontline DLBCL win AbbVie and Genmab's epcoritamab plus R-CHOP cut progression risk 51% in newly diagnosed DLBCL, the first Phase 3 win for a bispecific combo in frontline lymphoma. This validates bispecifics as mainstream therapy, expanding the treatable market and lifting the theme.
A major positive clinical validation for a new drug class that broadens oncology treatment options.
Genmab's ADC shines in hard-to-treat ovarian cancer Genmab's Rina-S produced a 45.9% response rate in platinum-resistant ovarian cancer, working even in patients with low folate receptor alpha and prior mirvetuximab. This supports the fast-growing ADC class and opens a new option for a tough-to-treat cancer.
Positive data for an ADC in an unmet-need setting, reinforcing the theme's technology momentum.
▼
Keytruda subcutaneous blocked in eight European markets A Dutch court barred Merck from selling subcutaneous Keytruda in eight European countries after Halozyme's patent win. This threatens Merck's plan to extend Keytruda's life before biosimilar competition, a setback for the dominant immunotherapy franchise.
A legal/regulatory blow to the biggest oncology drug, creating uncertainty for the incumbent immuno-oncology leader.
Lung cancer trial miss and buyback; Roche wins colon cancer approval Allist's furmonertinib missed its Phase 3 goal in EGFR exon 20 lung cancer, sending partner ArriVent down 47% and casting doubt on milestone payments. Meanwhile, Roche's Tecentriq won FDA approval as the first adjuvant immunotherapy for stage III dMMR colon cancer, cutting recurrence risk 50%.
Shows both a pipeline failure and a new regulatory approval, capturing the theme's mixed risk/reward.
Pfizer Trades at 9.6 Times 2026 Earnings as Guidance Points to Decline
Pfizer is trading at roughly 9.6 times the midpoint of its 2026 adjusted diluted EPS guidance range of $2.80 to $3.00, a discount that reflects expected earnings decline rather than a straightforward bargain. The 2026 EPS midpoint sits below the $3.075 midpoint of Pfizer's 2025 guidance, and the company expects 2026 revenue of $59.5 billion to $62.5 billion against approximately $62 billion in 2025 guidance, with COVID-19 products falling to about $5 billion from approximately $6.5 billion and loss-of-exclusivity products creating another $1.5 billion revenue headwind. Excluding COVID products and products facing loss of exclusivity, Pfizer expects approximately 4% operational revenue growth at the midpoint, suggesting a business in transition rather than one losing its ability to grow. On the pipeline side, Pfizer reported Phase 2b data in June for berobenatide, its investigational monthly GLP-1 receptor agonist, showing almost 16% non-placebo-adjusted weight loss at 32 weeks at the 2.4 mg weekly dose, and plans 10 Phase 3 studies in 2026 within a program of more than 20 obesity trials, while also highlighting next-generation oncology programs including a PD-1/VEGF bispecific antibody, an antibody-drug conjugate and a next-generation CDK4 inhibitor at ASCO 2026. Pfizer also reached settlements with generic manufacturers extending VYNDAMAX's effective U.S. patent expiry to June 1, 2031, versus a previous expectation of significant U.S. revenue decline beginning in 2029, and now expects VYNDAMAX revenue to remain relatively stable from 2028 through mid-2031, subject to other litigation, with 2026 adjusted R&D spending guided to $10.5 billion to $11.5 billion.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Technology
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Technology
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) Technology
Aging Population › Chronic-Disease Pharma Franchises Technology
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint Technology
PFE · Capital · Negative Pfizer's 2026 EPS and revenue guidance point to a decline, with COVID-19 products falling to about $5 billion from $6.5 billion and loss-of-exclusivity headwinds of $1.5 billion.
PFE · Regulation · Positive Pfizer's settlements with generic manufacturers extend VYNDAMAX's effective U.S. patent expiry to June 1, 2031, delaying expected revenue decline.
PFE · Technology · Positive Pfizer reported positive Phase 2b data for berobenatide with ~16% weight loss and plans 10 Phase 3 obesity studies in 2026, alongside next-generation oncology programs.
Moderna Fair Value Estimate Rises to US$122.67 on Cancer Vaccine Analyst Revisions
Moderna's fair value estimate has been lifted from US$119.56 to US$122.67 per share, according to updated modelling tied to analyst revisions on its intismeran cancer vaccine program. The change follows Phase 3 INTerpath-001 melanoma data that prompted target lifts or upgrades from BofA, Goldman Sachs, UBS, Barclays, RBC Capital and Morgan Stanley, with BofA setting a US$200 target and a Neutral rating and calling the readout a watershed moment for Moderna. William Blair moved to Outperform and Wolfe Research called the melanoma result de-risking for the broader intismeran platform, while RBC Capital described the data as a massive scientific breakthrough. On the bearish side, Citi and Rothschild & Co Redburn moved to Sell even as they raised targets to US$80 and US$81 respectively, citing questions on oncology revenue expectations and limited disclosure around efficacy metrics such as hazard ratios. The updated model also shifted the revenue growth assumption from 26.74% to 26.75%, the net profit margin from 17.25% to 17.20%, the future P/E from 80.90x to 83.10x, and the discount rate from 7.50% to 7.46%.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Technology
Biotech & Genomic Medicine › mRNA Platforms ▲Technology
Biotech & Genomic Medicine › RNA Therapeutics ▲Technology
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint Technology
MRNA · Capital · Positive Fair value estimate raised to US$122.67 and multiple analyst price-target increases/upgrades followed the data readout.
MRNA · Technology · Positive Phase 3 INTerpath-001 melanoma data for the intismeran cancer vaccine prompted analyst target lifts and upgrades, de-risking the platform.
Baili Tianheng's Izabren Combined with Radiotherapy for Head and Neck Squamous Cell Carcinoma Clinical Trial Approved by NMPA
Baili Tianheng announced on October 11 that the company recently received the official approval of the Drug Clinical Trial Approval Notice from the National Medical Products Administration. Its self-developed, first-in-class drug Izabren (luncombe izabren, BL-B01D1/iza-bren) combined with radiotherapy for the treatment of locally advanced unresectable head and neck squamous cell carcinoma and other solid tumors has been approved for clinical trials. The announcement stated that Izabren is the world's first and only approved EGFR×HER3 bispecific antibody-drug conjugate, and has currently initiated more than 45 clinical trials for multiple tumor types in China and the United States, including 20 Phase III clinical studies (including Phase II/III). Izabren has 9 indications included in the National Medical Products Administration's Center for Drug Evaluation breakthrough therapy designation list, 2 indications included in the priority review designation list, and some indications have also received marketing approval from the National Medical Products Administration. In mid-2026, Baili Tianheng achieved revenue of 0.0 yuan and a net loss attributable to the parent company of 1.637 billion yuan.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Regulation
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Regulation
688506.CG · Technology · Positive NMPA approved clinical trial of Baili Tianheng's first-in-class Izabren combined with radiotherapy for head and neck squamous cell carcinoma.
AbbVie Wins Two FDA Breakthrough Therapy Tags for Telisotuzumab Adizutecan
AbbVie received two FDA Breakthrough Therapy Designations for its experimental cancer drug telisotuzumab adizutecan in colorectal cancer and non small cell lung cancer. The designations apply to biomarker defined patient groups in those two large solid tumor indications, and they mark the first Breakthrough Therapy status for telisotuzumab adizutecan, which sits in AbbVie's antibody drug conjugate pipeline. Colorectal cancer and non small cell lung cancer together affect more than four million people worldwide each year, and the focus on biomarker defined groups, including c Met protein expressing NSCLC, points to narrower patient pools but potentially higher value treatment settings. The designations support the view that AbbVie needs its pipeline to replace aging blockbusters such as Humira and Imbruvica, with telisotuzumab adizutecan complementing oncology assets like etentamig. The next signpost is how the ongoing Phase 3 and Phase 2/3 telisotuzumab adizutecan studies progress and when AbbVie moves toward regulatory filings in colorectal cancer and non small cell lung cancer, building on the first in human M21 404 data.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Regulation
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Regulation
ABBV · Technology · Positive FDA granted two Breakthrough Therapy Designations for AbbVie's experimental telisotuzumab adizutecan in colorectal and NSCLC, advancing its ADC pipeline.
NovoCure Wins Japan Approval for Optune Pax in Pancreatic Cancer
NovoCure announced that Japan's Ministry of Health, Labour and Welfare approved Optune Pax, a portable Tumor Treating Fields device, for use with gemcitabine and nab-paclitaxel in adults with unresectable locally advanced pancreatic cancer. The decision, announced in October 2026, was based on the Phase 3 PANOVA-3 trial, which showed a statistically significant improvement in median overall survival. The approval extends TTFields therapy into a new, hard-to-treat solid tumor indication in Japan, supported by largely manageable skin-related side effects that may encourage clinician adoption. It builds directly on the February 2026 FDA approval of Optune Pax in locally advanced pancreatic cancer alongside gemcitabine and nab-paclitaxel, reinforcing the view that regulators in more than one major market consider the PANOVA-3 data clinically meaningful. NovoCure's narrative projects $915.6 million in revenue and $119.8 million in earnings by 2029, while some optimistic analysts assume revenue could reach about US$1.1 billion and earnings US$70 million by 2029.
Biotech & Genomic Medicine › Oncology Therapeutics Regulation
NVCR · Regulation · Positive Japan's MHLW approved Optune Pax for unresectable locally advanced pancreatic cancer, expanding TTFields into a new indication in Japan.
Akeso Doses First Patient in Phase III Perioperative Cadonilimab Colon Cancer Study
Akeso, Inc. announced that the first patient has been dosed in a Phase III clinical study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as monotherapy in the neoadjuvant/adjuvant perioperative treatment of resectable microsatellite instability-high or mismatch repair-deficient colon cancer. The trial, designated COMPASSION-40/AK104-313, marks a significant new indication for cadonilimab beyond gastric, lung, and cervical cancers, and is the 13th Phase III or registrational study of the therapy conducted globally. Colorectal cancer is among the malignancies with the highest incidence and mortality worldwide, and patients with MSI-H/dMMR colon cancer derive limited benefit from conventional perioperative chemotherapy, with pathological response rates of only approximately 7%. No immunotherapy has yet been approved anywhere for the perioperative treatment of localized MSI-H/dMMR colon cancer. Supporting evidence comes from a prior Phase II study of cadonilimab monotherapy as neoadjuvant treatment in MSI-H/dMMR colorectal cancer, where data presented at the 2024 ESMO Immuno-Oncology Congress showed a pathological complete response rate of 84.6% and a major pathological response rate of 100% among patients who proceeded to surgery, with a manageable safety profile.
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Technology
Biotech & Genomic Medicine › Oncology Therapeutics ▲Technology
9926.HK · Technology · Positive First patient dosed in Phase III trial of cadonilimab for perioperative MSI-H/dMMR colon cancer, a new indication with strong prior Phase II response data.
Allist Responds to Failure of Furmonertinib Overseas Phase III Clinical Study
Allist responded to media on October 9 regarding the failure of the overseas Phase III clinical study of its core product furmonertinib, stating that the FURVENT study data require further analysis and that the company will determine subsequent development and regulatory communication plans. The company believes the FURVENT study results will not affect furmonertinib's sales in the third quarter or in the future, as current sales of the drug mainly come from the first-line treatment indication for EGFR-sensitive mutations. Allist said that at the subsequent global investigator meeting for the FURVENT study, experts believed furmonertinib met prior efficacy expectations for EGFR exon 20 insertion mutations; the chemotherapy arm's progression-free survival assessed by blinded independent central review differed substantially from investigator-assessed results, and apart from this difference, other data for furmonertinib performed well. On the same day, the National Healthcare Security Administration separately published the first batch of primary-level disease categories, including 31 DRG primary-level disease groups and 127 DIP primary-level disease categories, for local implementation reference.
Biotech & Genomic Medicine › Oncology Therapeutics Technology
688578.CG · Technology · Negative Overseas Phase III FURVENT study of core product furmonertinib failed, requiring further data analysis and uncertain regulatory path.
Moderna shares surge on news of US-private partnership to develop cancer vaccines
Shares of Moderna and Novavax rose today after The New York Times reported that the US National Institutes of Health, or NIH, plans to launch a public-private partnership to accelerate the development of personalized cancer vaccines. The vaccine project is expected to begin in December, focusing on pancreatic cancer, liver cancer, and colorectal cancer, as well as certain tumors in children. Previous trials have used mRNA technology to train the body's immune system to recognize and attack proteins specific to cancer cells. The positive reaction to the news was most evident for Moderna, which is developing personalized mRNA cancer vaccines together with Merck. Moderna's share price has soared more than 600% since the start of this year, making it the best-performing stock among the companies used to calculate the S&P 500 index.
Biotech & Genomic Medicine › mRNA Platforms ▲Technology
Biotech & Genomic Medicine › RNA Therapeutics ▲Technology
Biotech & Genomic Medicine › Oncology Therapeutics ▲Technology
MRNA · Technology · Positive NIH public-private partnership to accelerate personalized mRNA cancer vaccines directly benefits Moderna's cancer vaccine program with Merck.
NVAX · Technology · Positive Novavax shares rose on the NIH cancer vaccine partnership news, though the article does not detail its specific role.
Pfizer Wins FDA Approval for Frontline TUKYSA Maintenance in HER2-Positive Breast Cancer
Pfizer has received U.S. FDA approval for TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a chemotherapy-free maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction therapy, expanding the drug into the frontline metastatic setting. The decision moves TUKYSA into an earlier phase of care for a broader patient group and reinforces Pfizer's growing emphasis on targeted oncology therapies, supported by Phase 3 HER2CLIMB-05 data. The approval fits Pfizer's narrative of shifting from a shrinking COVID portfolio toward a more oncology-led, specialty medicine story while keeping its sizeable dividend intact, though on its own it does not meaningfully change near-term dependence on cost savings and execution in obesity and oncology pipelines. Pfizer's narrative projects $54.3 billion in revenue and $9.1 billion in earnings by 2029, implying a 5.2% yearly revenue decline but an earnings increase of about $4.8 billion from $4.3 billion today, with a $28.88 fair value estimate representing 4% upside to the current price. The most relevant supporting development is Pfizer's fresh Phase 3 success with LITFULO in nonsegmental vitiligo, which, like TUKYSA, leans into higher value specialty care, while the recently affirmed US$0.43 quarterly dividend keeps income in focus.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Regulation
PFE · Regulation · Positive FDA approval expands TUKYSA into the frontline metastatic HER2-positive breast cancer maintenance setting, broadening its patient population.
Johnson & Johnson Q3 Earnings Preview: Estimates Cut, Stelara Biosimilar Pressure Looms
Johnson & Johnson will report its third-quarter 2026 results on Oct. 13, with the Zacks Consensus Estimate pegged at $25.37 billion in sales and $2.66 per share in earnings. Over the past 60 days, the consensus estimate for 2026 earnings has declined from $11.48 to $11.21 per share, while the 2027 estimate has fallen from $12.81 to $12.17. J&J has an Earnings ESP of +2.10% and a Zacks Rank #3 (Hold), and it exceeded earnings expectations in each of the trailing four quarters, delivering an average surprise of 1.39%. Within the Innovative Medicine segment, consensus estimates stand at $4.33 billion for Darzalex, $2.24 billion for Tremfya and $1.07 billion for Erleada, while Stelara sales are seen at $634.0 million and Imbruvica at $602.0 million, with Stelara's loss of exclusivity having cut the segment's growth by 760 basis points in the second quarter. The MedTech segment carries a consensus estimate of $8.77 billion, and J&J still expects to generate more than $100 billion in revenues in 2026 after $49.4 billion in the first half.
Aging Population › Chronic-Disease Pharma Franchises ▼Demand
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics Demand
Biotech & Genomic Medicine › Oncology Therapeutics Demand
JNJ · Capital · Negative Consensus 2026/2027 EPS estimates cut ahead of Q3 report, with Stelara loss of exclusivity dragging Innovative Medicine growth.
FDA Approves Roche's Tecentriq for Stage III dMMR Colon Cancer
The FDA has approved Tecentriq and Tecentriq Hybreza, in combination with fluoropyrimidine and oxaliplatin chemotherapy, for the adjuvant treatment of stage III deficient DNA mismatch repair colon cancer, marking the 12th U.S. indication for Roche's cancer immunotherapy. The decision was based on the phase III ATOMIC study, which enrolled 712 patients with stage III dMMR colon cancer and showed that adding Tecentriq reduced the risk of disease recurrence or death by 50% compared with chemotherapy alone, with a 36-month disease-free survival rate of 86% versus 76% for chemotherapy alone. The approval makes Tecentriq the first approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, and Roche plans additional regulatory filings including a submission to the European Medicines Agency. Tecentriq generated sales of CHF 1.7 billion in the first half of 2026, up 6%. Roche shares have risen 3.5% year to date.
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Regulation
Biotech & Genomic Medicine › Oncology Therapeutics ▲Regulation
ROP.SW · Regulation · Positive FDA approves Tecentriq as first adjuvant immunotherapy for stage III dMMR colon cancer, expanding Roche's label and sales potential.
India caps profit margins on non-scheduled cancer drugs at 30%
The Indian government has announced that it will cap retail profit margins on cancer medicines at no more than 30%, in response to complaints that cancer drug prices in the country have continued to soar over the past several years. The profit cap applies only to cancer drugs outside the scheduled medicines list, known as non-scheduled drugs, since the government already sets strict maximum ceiling prices for essential cancer treatments that are on the scheduled list. The Department of Pharmaceuticals, under India's Ministry of Chemicals and Fertilizers, said in an official statement that the measure will help reduce the cost burden for cancer patients in the country by about 25 billion rupees, or roughly 258.7 million US dollars, per year. An expert committee under the Department of Health Services is currently drawing up and finalising the list of drugs that will fall under the measure, after which the National Pharmaceutical Pricing Authority will review the matter and issue an official notification. Surveys have found that non-scheduled cancer drugs carry average markups of as much as 170% over cost, with some drugs rising by 700% or more, as prices surge through the supply chain before reaching patients.
MicuRx Pharmaceuticals and ClearideBio sign exclusive license and platform collaboration agreement for MRX-23, with total milestone payment cap of 750 million US dollars
MicuRx Pharmaceuticals announced that it plans to sign an exclusive license agreement for the MRX-23 program and a platform technology collaboration agreement with ClearideBio of Switzerland. The former involves a worldwide exclusive license for the MRX-23 program; the latter is a multi-program option collaboration based on the company's independently developed STOPIN antibody-drug conjugate platform with a novel camptothecin payload, under which ClearideBio may exercise options for an agreed number of targets or target combinations in accordance with the agreement. Under the MRX-23 license agreement, an upfront payment of 1 million US dollars will be paid as agreed after the agreement takes effect, and this payment is non-refundable once made. Near-term development milestone payments are triggered by the first approval of a clinical trial application for the licensed product. The nominal cap on research, registration, and sales milestone payments for MRX-23 totals 223 million US dollars; when all options under the platform collaboration are exercised and all milestones are achieved, the total payment cap is 750 million US dollars.
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Technology
Biotech & Genomic Medicine › Oncology Therapeutics ▲Technology
688373.CG · Capital · Positive MicuRx signs exclusive license and platform collaboration for MRX-23 with up to $750M in milestone payments, including $1M upfront.
ClearideBio Therapeutics AG · Capital · Positive ClearideBio secures worldwide exclusive license to MRX-23 and options on MicuRx's STOPIN ADC platform under the collaboration.
Kexing Pharmaceutical's GB-K02 Drug Marketing Authorization Application Accepted
Kexing Pharmaceutical disclosed in an announcement on the evening of October 9 that the company has received the Acceptance Notice issued by the National Medical Products Administration, and the marketing authorization application for its investigational drug pegylated human granulocyte colony-stimulating factor injection GB-K02 has been accepted. The announcement shows that GB-K02 is indicated to reduce the incidence of infection manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Biotech & Genomic Medicine › Oncology Therapeutics Regulation
688136.CG · Technology · Positive NMPA accepted the marketing authorization application for its investigational drug GB-K02, advancing the product toward approval.
Northwest Biotherapeutics and NHS Blood and Transplant Collaborate on DCVax-L Production
Northwest Biotherapeutics and the UK National Health Service Blood and Transplant have entered into a collaboration to support production of the company's experimental cancer vaccine DCVax-L. NHSBT's Therapeutic Apheresis Services is carrying out leukapheresis procedures to collect the immune cell starting material needed for the DCVax-L treatment, while its Cellular and Molecular Therapies team is providing specialist cell processing and handling of cellular material, working with Northwest Biotherapeutics and Advent Bioservices. The collaboration initially involves Leeds and Oxford, and the parties are exploring phased expansion of the model to additional NHSBT locations across England. Northwest Biotherapeutics CEO Linda Powers said NHSBT's capabilities can significantly enhance the scale-up and accessibility of DCVax-L, and NHSBT Medical Director Dr James Griffin said the aim is to help make cutting edge advanced therapies more accessible. DCVax-L is a treatment for Glioblastoma multiforme, an aggressive form of primary brain cancer, as well as all solid tumours, and Northwest Biotherapeutics has submitted a Marketing Authorisation Application for commercial approval in the UK that is currently undergoing review.
Northwest Biotherapeutics · Demand · Positive NHSBT collaboration supports scale-up and accessibility of DCVax-L production, advancing the company's lead cancer vaccine
Advent Bioservices · Demand · Positive Advent Bioservices is named as a partner working with NHSBT and Northwest Biotherapeutics on DCVax-L cell processing, gaining involvement in the collaboration
Guardant360 CDx Wins European Approval as Companion Diagnostic for AstraZeneca's ETCAMAH
Guardant Health announced that Guardant360 CDx has received CE-marking under Europe's In Vitro Diagnostic Medical Devices Regulation as a companion diagnostic for AstraZeneca's ETCAMAH, also known as camizestrant, in advanced ER-positive breast cancer. The test identifies patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from the next-generation oral selective estrogen receptor degrader and complete ER antagonist. Using a simple blood draw, clinicians can test for ESR1 mutations ahead of disease progression, and the European approval follows prior regulatory approvals of Guardant360 CDx as a companion diagnostic for ETCAMAH in the United States and Japan. The clearance marks the third companion diagnostic approval for ETCAMAH and the 31st companion diagnostic approval for Guardant Health. Chairman and co-CEO Helmy Eltoukhy said the company sees tremendous potential for this testing protocol to transform the treatment of other cancer types.
Biotech & Genomic Medicine › Diagnostics & Precision Testing ▲Regulation
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Regulation
Biotech & Genomic Medicine › Oncology Therapeutics Regulation
GH · Regulation · Positive Guardant360 CDx received CE-marking in Europe as a companion diagnostic for AstraZeneca's camizestrant, its 31st companion diagnostic approval.
AZN.LSE · Regulation · Positive European approval of Guardant360 CDx as a companion diagnostic supports use of AstraZeneca's ETCAMAH/camizestrant in advanced ER-positive breast cancer.
Merck Wins FDA Approval for WELIREG Plus LENVIMA in Kidney Cancer
Merck received FDA approval for WELIREG plus LENVIMA in adults with advanced renal cell carcinoma following prior PD-1/PD-L1 therapy. The approved regimen combines WELIREG at 120 mg once daily with LENVIMA at 20 mg once daily. Separately, Merck began a first-in-human Phase I trial using Cyprumed's oral peptide delivery platform for an undisclosed peptide candidate. The approval expands Merck's oncology portfolio beyond Keytruda, while the Cyprumed trial carries execution risk for the company's newer oral peptide technology.
AstraZeneca Seeks FDA Approval for ORPATHYS-TAGRISSO Lung Cancer Combination
AstraZeneca has applied to the US Food and Drug Administration for approval of ORPATHYS-TAGRISSO, a combination developed with HUTCHMED for advanced lung cancer that has progressed during or after EGFR-targeted therapy. The filing is supported by the 338-patient Phase 3 SAFFRON trial, which showed statistically significant improvements in both progression-free survival and overall survival, and the opportunity is meaningful because approximately 34% of tumors develop high levels of MET overexpression or amplification after progression. If approved, the combination would expand the use of Tagrisso, AstraZeneca's key oncology medicine, which recorded a 6% increase in second-quarter sales to $1.94 billion; the ORPATHYS-Tagrisso combination is already approved in China for a specified EGFR-mutated lung cancer population, so US approval could expand its geographic reach. The addressable population is narrower than Tagrisso's broader market, however, and even with approval the combination is unlikely to materially alter the current earnings profile in the near term. AstraZeneca closed at $156.90 on October 2, trading at approximately 15x forward earnings and 23.5x trailing earnings, with management targeting $80 billion in annual revenue by 2030, about 6.4% annual growth from the $58.7 billion generated in 2025.
Biotech & Genomic Medicine › Oncology Therapeutics Regulation
AZN.LSE · Regulation · Positive AstraZeneca filed for FDA approval of the ORPATHYS-TAGRISSO combination, supported by positive Phase 3 SAFFRON survival data, potentially expanding Tagrisso's use.
0013.HK · Regulation · Positive AstraZeneca's FDA filing for the ORPATHYS-TAGRISSO combination, co-developed with HUTCHMED, advances a regulatory approval that could expand the drug's reach beyond China.
Dutch Court Blocks Merck's Keytruda SC in Eight European Markets
A Dutch patent court has ruled in favor of Halozyme Therapeutics, finding that Merck's subcutaneous formulation of Keytruda infringes one of Halozyme's MDASE patents covering technology used to deliver drugs through subcutaneous injection. The ruling orders Merck to stop manufacturing and selling Keytruda SC in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands, and bars Merck from letting its affiliates continue selling the drug in those markets, including through its European marketing authorization. The order does not affect the intravenous version of Keytruda, which remains available to patients because it is not covered by Halozyme's patent or the injunction. It marks the second legal victory for Halozyme over Keytruda SC, following a December 2025 German preliminary injunction that stopped Merck from distributing or offering the drug in Germany, and Halozyme has also filed a separate U.S. patent infringement lawsuit alleging that Keytruda SC, marketed as Keytruda Qlex, infringes 15 of its MDASE patents. Merck said it strongly disagrees with the Dutch decision, considers Halozyme's patent invalid globally and the infringement allegation without merit, and is evaluating its next steps. The ruling is a setback for Merck as it seeks to expand Keytruda's use ahead of the loss of U.S. patent protection for the original formulation, with biosimilar competition potentially beginning in December 2028; the IV and SC versions together generate nearly half of Merck's topline. Halozyme said the MDASE technology in the Merck dispute is separate from its ENHANZE technology and licensing program, which is a major source of royalty revenue and has been used in 10 commercialized products across more than 100 markets, including Johnson & Johnson's Darzalex and argenx's Vyvgart. Halozyme shares have surged 65% year to date compared with the industry's 1% growth.
Biotech & Genomic Medicine › Oncology Therapeutics ▼Competition
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▼Competition
HALO · Regulation · Positive Dutch patent court ruled in Halozyme's favor, blocking Merck's Keytruda SC in eight European markets over its MDASE patent.
MRK · Regulation · Negative Injunction bars Merck from making and selling Keytruda SC in eight European markets, a setback to expanding the drug ahead of patent loss.
Pfizer Oncology Sales Seen Rising on Padcev, Lorbrena Ahead of Q3 Results
Pfizer is expected to report higher oncology sales in the third quarter of 2026, driven by key drugs Padcev, Lorbrena and the Braftovi-Mektovi combination, which should offset declining sales of Ibrance and Adcetris. Oncology comprises around 27% of Pfizer's total revenues, and in the second quarter of 2026 oncology revenues increased 3% to $4.17 billion, with 2% operational growth. The Zacks Consensus Estimate for Padcev is $692 million, while that for Ibrance is $1.01 billion. Pfizer, which markets six cancer biosimilars, is also expected to provide updates on key oncology candidates on its third-quarter conference call, including atirmociclib, sasanlimab and sigvotatug vedotin, as well as PF-08634404, a dual PD-1/VEGF inhibitor in-licensed from Chinese biotech 3SBio in 2025 for which Pfizer has initiated nine studies, including two pivotal phase III trials. Pfizer will announce its third-quarter results on Nov. 3.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Demand
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Demand
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Demand
PFE · Demand · Positive Expected higher oncology sales in Q3 driven by Padcev, Lorbrena and Braftovi-Mektovi offsetting declines in Ibrance and Adcetris.
1530.HK · Demand · Positive Pfizer in-licensed PF-08634404 from 3SBio and has initiated nine studies including two pivotal phase III trials, implying milestone/royalty potential for 3SBio.
FDA Approves Pfizer's Tukysa Combo for Front-Line Maintenance in HER2-Positive Breast Cancer
The FDA has approved Pfizer's Tukysa, or tucatinib, in combination with Roche's Herceptin and Perjeta for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. The approval expands Tukysa into the frontline setting, providing a chemotherapy-free maintenance option beyond its existing second-line indication, and was supported by data from the phase III HER2CLIMB-05 study. In that study, the Tukysa regimen reduced the risk of disease progression or death by 35.9% versus placebo plus Herceptin and Perjeta, with median progression-free survival of 24.9 months versus 16.3 months, an 8.6-month improvement. The safety profile was generally consistent with the drug's known profile, though hepatotoxicity was more severe. Tukysa came to Pfizer through the December 2023 acquisition of Seagen, which added four antibody-drug conjugates: Adcetris, Padcev, Tukysa and Tivdak.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Regulation
PFE · Regulation · Positive FDA approves Pfizer's Tukysa combo for front-line maintenance in HER2-positive breast cancer, expanding the drug into the frontline setting
Moderna to Join Nasdaq-100, Replacing Warner Bros. Discovery
Moderna will join the Nasdaq-100 Index on Oct. 9, replacing Warner Bros. Discovery before the opening bell on Friday. The swap follows the completion of Paramount's acquisition of Warner Bros. Discovery, whose shares have ceased trading; the combined entity is now named Skydance and trades on the NYSE under the ticker SKYD. Nasdaq did not cite a specific reason for adding Moderna, but the inclusion follows a sharp rise in the company's market value and growing optimism around its prospects, supported by positive phase III results for its personalized cancer therapy developed with Merck, which met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in certain high-risk melanoma patients. The Nasdaq-100 is tracked by more than 200 investment products with over $800 billion in assets under management globally, so index funds adjusting their portfolios could create incremental institutional demand for Moderna shares. The inclusion does not change Moderna's underlying fundamentals, operations, cash flow or pipeline development, and the stock's longer-term performance will continue to depend on its business and pipeline. Moderna shares have skyrocketed 566% year-to-date, far outpacing the industry's 1% growth, and the stock trades at 30.84 times forward 12-month sales on a price-to-sales basis versus an industry average of 2.06 times.
Biotech & Genomic Medicine › mRNA Platforms ▲Capital
Biotech & Genomic Medicine › RNA Therapeutics ▲Capital
Biotech & Genomic Medicine › Oncology Therapeutics ▲Capital
MRNA · Capital · Positive Moderna will join the Nasdaq-100 on Oct. 9, and index funds tracking the index could create incremental institutional demand for its shares.
WBD · Capital · Neutral Warner Bros. Discovery is being removed from the Nasdaq-100 after Paramount completed its acquisition and its shares ceased trading.
Eli Lilly Oncology Sales Seen at $2.65 Billion Ahead of Q3 Earnings
Eli Lilly is expected to report third-quarter results on Oct. 29, with the Zacks Consensus Estimate for its overall oncology portfolio sales pegged at $2.65 billion. The franchise generated $4.84 billion in revenues in the first half of 2026, up 11% year over year, as newer products increasingly contributed to growth. A significant portion of oncology revenues is expected to come from blockbuster breast cancer drug Verzenio, with sales likely to have remained flat or declined in the quarter, while Retevmo and Jaypirca are expected to have supported growth, with Jaypirca benefiting from increasing use in chronic lymphocytic leukemia and mantle cell lymphoma. Growth from newer products is likely to have been partially offset by declining sales of older drugs such as Alimta and Cyramza amid increasing competition from immuno-oncology therapies in the United States. Eli Lilly secured FDA approval for its new breast cancer drug Inluriyo in late 2025 and subsequently launched it in the United States, and investors expect the drug's sales to have risen sequentially in the third quarter.
InnoCare Pharma Signs Eli Lilly License Deal for Up to Five Drug Targets
InnoCare Pharma announced a research collaboration and license agreement with Eli Lilly to pursue up to five drug targets addressing critical unmet medical needs. The deal headlines arrive after a weaker patch for the company's shares, with the 7 day share price return down 8.65% and the 30 day share price return down 8.72%, though the year to date share price return is 8.08% and the 3 year total shareholder return is 119.32%. Against InnoCare Pharma's last close of HK$13.51, the most followed narrative anchors fair value at HK$19.62, framing the shares as 31% undervalued under a 7.25% discount rate. The company's pipeline includes late-stage drugs tafasitamab and zurletrectinib, and it is introducing an ADC platform intended to open new revenue streams. Still, the story leans heavily on a few key drugs and rising R&D spending, and the current P/E of 21.4x sits above a fair ratio of 9.8x but below a Hong Kong biotech average of 18.4x.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Technology
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Technology
688428.CG · Demand · Positive InnoCare signs a research collaboration and license agreement with Eli Lilly covering up to five drug targets, a concrete pipeline/partnering win.
LLY · Demand · Neutral Eli Lilly is the licensing partner in the up-to-five-target research collaboration, but the deal's terms and benefit to Lilly are not detailed.
Biohaven Signs Regeneron Supply Deal for BHV-1530 Cancer Combination
Biohaven Ltd. announced a clinical supply agreement with Regeneron Pharmaceuticals in September 2026 to test BHV-1530 in combination with cemiplimab, sold as Libtayo, in patients with solid tumors. The BHV-1530 collaboration follows earlier monotherapy and preclinical data suggesting potential synergy with Anti-PD-1 therapy, and it builds on an existing supply agreement covering Biohaven's next-generation TROP2-directed ADC BHV-1510, deepening Regeneron's involvement across Biohaven's oncology pipeline. The company has no revenue yet, carries very large ongoing losses, and depends on future trial readouts and capital markets rather than cash flow. Near-term swing factors include upcoming data from opakalim in focal epilepsy, the MoDE autoimmune programs, and obesity results from taldefgrobep, with regulatory progress on troriluzole also in focus. Investors in the Simply Wall St Community hold only two fair value views on Biohaven, spanning from about US$21 to nearly US$70 per share.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Supply
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Supply
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Supply
BHVN · Demand · Positive Biohaven signed a clinical supply agreement with Regeneron to test BHV-1530 in combination with cemiplimab, advancing its oncology pipeline.
REGN · Demand · Positive Regeneron will supply cemiplimab (Libtayo) for the combination trial, deepening its involvement across Biohaven's oncology pipeline.
Changchun High-Tech Subsidiary GeneScience Pharmaceutical Receives Drug Registration Certificate for Leuprorelin Mesylate Injection
Changchun High-Tech Industries announced that its controlling subsidiary GeneScience Pharmaceutical has received a Drug Registration Certificate issued by the National Medical Products Administration, with approval granted for the overseas-manufactured marketing authorization application of Leuprorelin Mesylate Injection (6M). The approved indication is prostate cancer requiring androgen deprivation therapy. The product is a long-acting subcutaneous injection with a six-month dosing interval, which can improve patient medication adherence. This approval is conducive to enriching the company's product portfolio in the oncology field and enhancing its market competitiveness.
Betta Pharmaceuticals Subsidiary's BPI-572270 Capsules Receive US FDA Clinical Trial Approval
Betta Pharmaceuticals disclosed in an announcement on the evening of October 7 that the clinical trial application for BPI-572270 capsules, filed by its wholly owned subsidiary Hangzhou Jingyao Biotechnology Co., Ltd., has been approved by the US Food and Drug Administration. The announcement shows that BPI-572270 is a new molecular entity compound independently developed by Betta Pharmaceuticals with full independent intellectual property rights. It is a novel, potent pan-RAS non-degrading molecular glue inhibitor intended for the treatment of advanced solid tumors.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Technology
300558.CS · Technology · Positive US FDA approved clinical trial application for its independently developed BPI-572270 pan-RAS inhibitor for advanced solid tumors.
Dutch Court Blocks Merck's Subcutaneous Keytruda in Eight European Markets
A Dutch court ruled in favor of Halozyme Therapeutics in late September 2026, issuing an injunction that halts manufacture and sale of Merck's subcutaneous Keytruda across eight European countries following a patent dispute. The decision affects one of Merck's key immuno-oncology formulations in important European markets, though it leaves the central near-term catalyst around late-stage oncology and cardiometabolic launches unchanged. Separately, Merck secured a new global license for SciBrunch's preclinical KRAS G12D inhibitor SPR2015, a deal carrying a US$400 million upfront charge that will weigh on reported earnings in the near term. Merck's narrative projects $75.3 billion in revenue and $22.5 billion in earnings by 2029, requiring 4.2% yearly revenue growth and a $19.3 billion earnings increase from $3.2 billion today, with a $155.68 fair value implying 10% upside. Some of the most optimistic analysts model roughly US$82.1 billion in revenue and US$30.2 billion in earnings by 2029, weighting pipeline breadth and AI-enabled efficiency more heavily than access risks such as the subcutaneous Keytruda ruling.
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▼Regulation
Biotech & Genomic Medicine › Oncology Therapeutics ▼Regulation
HALO · Regulation · Positive Dutch court injunction in Halozyme's favor halts Merck's subcutaneous Keytruda across eight European markets, a legal win for Halozyme.
MRK · Regulation · Negative Injunction blocks manufacture and sale of subcutaneous Keytruda in eight European markets following the patent dispute.
MRK · Capital · Negative Separate SciBrunch KRAS G12D license carries a US$400 million upfront charge that will weigh on near-term reported earnings.
Bristol Myers' Reblozyl Sales Near $1.3 Billion as FDA Sets 2027 Decision Date
Bristol Myers Squibb is counting on Reblozyl, the thalassemia drug it co-developed with Merck, to help drive top-line growth as legacy drug sales decline, with the treatment's sales nearing $1.3 billion in the first half of 2026, up 23% from the year-ago period. The drug's strong sales reflect solid uptake in first-line MDS-associated anemia, continued strength in the second-line setting and further penetration in the first-line RS-negative population. The FDA has accepted a supplemental biologics license application for Reblozyl with concomitant janus kinase inhibitor therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell transfusions, supported by the late-stage INDEPENDENCE study, and granted a target action date of March 11, 2027. A phase III study called ELEMENT-MDS, evaluating Reblozyl in first-line non-transfusion dependent low or intermediate risk MDS associated anemia, is ongoing, with data expected in 2028. In the competitive landscape, Geron Corporation's Rytelo generated $57.5 million of revenues in the second quarter of 2026 and is expected to post 2026 sales of $220-$240 million, while Keros Therapeutics expects a $20 million development milestone payment from partner Takeda after dosing the first patient in the late-stage ELRiSE MF study.
Biotech & Genomic Medicine › Oncology Therapeutics Demand
BMY · Demand · Positive Reblozyl sales near $1.3B in H1 2026, up 23% on strong uptake in first-line MDS-associated anemia and other settings.
BMY · Regulation · Positive FDA accepted supplemental BLA for Reblozyl with JAK inhibitor therapy in myelofibrosis-associated anemia, setting a March 11, 2027 action date.
MRK · Demand · Positive Merck co-developed Reblozyl, whose sales near $1.3B in H1 2026, up 23%, benefiting its partnered drug.
GERN · Competition · Neutral Geron's Rytelo posted $57.5M in Q2 2026 revenue and is expected to reach $220-$240M in 2026, mentioned as a competitor in the landscape.
KROS · Capital · Neutral Keros expects a $20M development milestone payment from Takeda after dosing the first patient in the ELRiSE MF study.
Caribou Biosciences Hits All-Time Low After RBC and Leerink Downgrades on Strategic Review
Caribou Biosciences shares fell to an all-time low on Wednesday after the cell therapy developer said it will explore strategic alternatives, prompting downgrades from RBC Capital Markets and Leerink Partners. The Berkeley, California-based company announced workforce and cost reductions and plans to halt its allogeneic CAR-T programs, vispa-cel and CB-011. Leerink analyst Daina Graybosch downgraded Caribou to Market Perform from Outperform and cut her price target to $1 from $4, citing the significant capital requirement to fund the planned Phase 3 ANTLER-3 trial for lead asset vispa-cel and decreased visibility into the company as an ongoing business. RBC Capital Markets analyst Luca Issi also downgraded Caribou to Sector Perform from Outperform and slashed his price target to $1 from $10 per share.
Biotech & Genomic Medicine › Gene & Cell Editing ▼Capital
CRBU · Capital · Negative Caribou announced a strategic review, workforce/cost cuts, and halted its allogeneic CAR-T programs, prompting RBC and Leerink downgrades and price-target slashes to $1.
Tempus Expands Multi-Year Collaboration with Moderna and Merck for Intismeran Autogene
Tempus announced an expanded, multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene, also known as V940 or mRNA-4157, a potential first-in-class individualized neoantigen therapy being evaluated in combination with KEYTRUDA in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside the United States and Canada, and the new collaboration builds on joint efforts initiated last year. Under the agreement, Tempus will manage the timely collection and transfer of tumor tissue and blood samples required for next-generation sequencing, and, subject to applicable regulatory approvals, will also provide NGS services to support the intismeran autogene design and manufacturing process. Financial terms of the collaboration were not disclosed. Moderna Chief Business Officer Said Francis said the partnership lets the company leverage Tempus's commercial footprint and advanced sequencing capabilities, while Jannie Oosthuizen, President of Global Oncology and MSD International, said such collaborations are helping build the infrastructure needed to bring individualized neoantigen therapies to patients at scale.
Biotech & Genomic Medicine › mRNA Platforms ▲Supply
Biotech & Genomic Medicine › Oncology Therapeutics ▲Supply
Biotech & Genomic Medicine › RNA Therapeutics ▲Supply
Biotech & Genomic Medicine › Diagnostics & Precision Testing ▲Supply
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Supply
TEM · Demand · Positive Tempus wins an expanded multi-year collaboration to provide tissue/blood collection and NGS services for intismeran autogene.
MRK · Demand · Positive Expanded collaboration supports commercialization of intismeran autogene, which Merck co-develops with Moderna and evaluates with KEYTRUDA.
MRNA · Demand · Positive Moderna's jointly developed intismeran autogene gains Tempus support for sample collection, NGS design, and manufacturing toward commercialization.
AstraZeneca Opens US$1b R&D Center in Kendall Square
AstraZeneca has opened a new US$1b global research and development center in Kendall Square, Massachusetts, consolidating its US work in oncology, cell therapy, chronic and rare diseases, and obesity into a single expanded hub. The site uses robotics and AI-enabled automation to support the company's research programs and broader drug development efforts. AstraZeneca is a GB-based biopharmaceutical group with a £185.5 billion market cap that spends heavily on discovering and developing prescription medicines. The company said the center tightens the link between early science and late-stage assets, which could affect how quickly it refines drug candidates and retires weaker programs. Investors will be watching for Phase II or Phase III readouts in obesity, COPD and key oncology programs over 2027 to 2029 as markers of whether the build-out is translating into a more resilient portfolio mix.
Biotech & Genomic Medicine › Oncology Therapeutics Capital
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Capital
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint Capital
Biotech & Genomic Medicine › Cell Therapy (CAR-T & beyond) Capital
AZN.LSE · Technology · Positive AstraZeneca opened a $1B R&D center using robotics and AI to speed drug discovery and refine candidates across oncology, cell therapy, and obesity.
Genmab Reports Phase 3 Win for Epcoritamab and Phase 1/2 Data for Rina S
Genmab posted two fresh oncology trial readouts, including a Phase 3 win for epcoritamab in newly diagnosed diffuse large B cell lymphoma. The EPCORE DLBCL 2 trial, run with AbbVie, reported that epcoritamab plus R CHOP cut the risk of disease progression or death by 51% versus R CHOP alone in patients with higher risk DLBCL. Separately, the Phase 1/2 RAINFOL 01 study of rinatabartsesutecan, or Rina S, in platinum resistant ovarian cancer reported a 45.9% confirmed objective response rate in a heavily pretreated population, with a median duration of response of 12.1 months and no clear safety signals around eye toxicity, peripheral neuropathy, interstitial lung disease or stomatitis. The trial headlines arrive after a strong run in the shares, with the DKK2,482.0 price coming alongside a 31.18% 90 day share price return and a 23.67% year to date share price return, while the 5 year total shareholder return is down 8.75%.
Enliven and FDA Agree on Phase 3 Design for Relcobatinib in CML
Enliven Therapeutics and the US FDA have agreed on a design for the phase 3 trial of relcobatinib for chronic myeloid leukemia in patients who have failed on prior treatments. The trial, called ENABLE-2, plans to enroll 450 adults with CML who were previously on one or more tyrosine kinase inhibitors. Participants will be randomized to receive either relcobatinib 80 mg once daily or an investigator-selected second-generation TKI. The primary endpoint is major molecular response at week 24. Relcobatinib, also known as ELVN-001, is a kinase inhibitor designed to specifically target the BCR::ABL1 gene fusion, which promotes the development of CML.
Biotech & Genomic Medicine › Oncology Therapeutics Regulation
ELVN · Technology · Positive FDA agreement on the phase 3 ENABLE-2 design for relcobatinib (ELVN-001) advances the company's lead drug development in CML.
Multiply Labs Raises $75 Million Series B Led by Patrick Soon-Shiong
Multiply Labs announced a $75 million Series B round, bringing its total capital raised to over $100 million since its founding in 2016. The round was led by Dr. Patrick Soon-Shiong with NantWorks, joined by new investors AstraZeneca, Lingotto, Teradyne, and Strange Ventures, alongside returning investors Casdin Capital, Lux Capital, Fifty Years, Ora Global, and Founders Fund. The San Francisco-based physical AI company automates biologics manufacturing with robotic clusters that integrate into existing instruments and processes without requiring a new facility, delivering a 74% reduction in cost per dose and up to 100 times more throughput than manual manufacturing. Beginning with cell and gene therapy and now expanding to advanced biologics including antibodies, viral vectors, and mRNA, the platform is owned and operated directly by pharmaceutical and biologics companies rather than run as an outsourced service. Multiply Labs will use the capital to expand manufacturing capacity, accelerate its product roadmap, and scale its team across engineering, regulatory, and commercial functions as it moves from clinical-stage deployments toward commercial-scale production.
Genmab Shares Jump 10.7% on Positive Phase III EPCORE DLBCL-2 Data
Genmab A/S Sponsored ADR shares rallied 10.7% in the last trading session to close at $38.48, following positive top-line results from the phase III EPCORE DLBCL-2 study. Genmab and its partner AbbVie announced that epcoritamab in combination with R-CHOP demonstrated a statistically significant improvement in progression-free survival in patients with newly diagnosed diffuse large B-cell lymphoma. The company is expected to post quarterly earnings of $0.37 per share in its upcoming report, a year-over-year change of -43.1%, on revenues of $1.18 billion, up 15.7% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 8.7% higher over the last 30 days, and the stock currently carries a Zacks Rank #3 (Hold).
Orion Pharma signs European distribution deal with Qilu Pharma Europe for pembrolizumab biosimilar
Orion Corporation, known as Orion Pharma, has entered into an agreement with Qilu Pharma Europe to commercialise an intravenous pembrolizumab biosimilar in Europe. Under the terms, Orion Pharma gains the exclusive right to distribute, market and sell Qilu's IV pembrolizumab biosimilar across Europe, while Qilu will supply the product and receive a share of profits plus certain development, regulatory and sales milestone payments. Pembrolizumab is an immune checkpoint inhibitor used to treat various cancers, and Qilu is currently developing the IV version. Satu Ahomäki, EVP Generics and Consumer Health at Orion Pharma, said the deal expands the company's strategic partnership with Qilu and brings its division closer to its long-term targets and strategic goals. Orion Pharma reported net sales of EUR 1,890 million in 2025 and employs about 4,000 professionals worldwide.
Biotech & Genomic Medicine › Biosimilars ▲Competition
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Competition
Biotech & Genomic Medicine › Oncology Therapeutics ▲Competition
0M2N.LSE · Demand · Positive Orion gains exclusive European rights to distribute, market and sell Qilu's IV pembrolizumab biosimilar, expanding its product portfolio and sales reach.
0M2O.LSE · Demand · Positive Orion B shares benefit from the same exclusive European distribution deal for Qilu's pembrolizumab biosimilar.
271560.KO · Demand · Positive Orion Corp is the parent entity behind Orion Pharma, which secured exclusive European commercialization rights for the pembrolizumab biosimilar.
Qilu Pharma Europe · Demand · Positive Qilu Pharma Europe secures a European commercialization partner and will receive profit share plus development, regulatory and sales milestones for its pembrolizumab biosimilar.
Moderna's mRNA Cancer Vaccine Moves Beyond Melanoma Into Broader Tumor Tests
Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma into a broader test across harder-to-treat solid tumors, with the central investor question being whether a platform validated in one cancer type can deliver meaningful results across a wider range of tumor biology. Moderna announced Phase 3 melanoma data at ESMO alongside pancreatic cancer and NSCLC materials, outlining its multi-tumor development pathway for intismeran autogene, which it is developing in partnership with Merck across melanoma, pancreatic cancer, and non-small-cell lung cancer indications. BioNTech is the clearest pharmaceutical-scale competitor, with BNT113 targeting HPV16-positive head-and-neck cancer and autogene cevumeran, a Roche-partnered program, active in pancreatic cancer. Citi downgraded Moderna on valuation concerns following the melanoma result, arguing that implied sales and expansion expectations were aggressive, while Pfizer, BioNTech, and Moderna face ongoing litigation over mRNA technology patents. Evaxion announced two-year data for EVX-01, an AI-designed personalized peptide vaccine in advanced melanoma, illustrating competitive intensity around individualized immune therapies beyond the mRNA modality. Manufacturing complexity remains a constraint, as each patient requires tumor sequencing, neoantigen selection, and individualized production within a clinically useful timeframe.
Biotech & Genomic Medicine › mRNA Platforms Technology
Biotech & Genomic Medicine › RNA Therapeutics Technology
Biotech & Genomic Medicine › Oncology Therapeutics Technology
MRNA · Technology · Neutral Moderna's personalized mRNA cancer vaccine moves beyond melanoma into broader solid-tumor tests with Phase 3 melanoma data and pancreatic/NSCLC materials
MRNA · Capital · Negative Citi downgraded Moderna on valuation concerns, arguing implied sales and expansion expectations were aggressive
MRK · Demand · Positive Merck is Moderna's partner developing intismeran autogene across melanoma, pancreatic, and NSCLC, with Phase 3 melanoma data and broader tumor expansion advancing the partnered program
22UA.XETRA · Competition · Neutral BioNTech is named the clearest pharmaceutical-scale competitor with BNT113 and Roche-partnered autogene cevumeran in pancreatic cancer
Summit Therapeutics, AstraZeneca and Daiichi Sankyo to Study Ivonescimab Plus Datroway Combos
Summit Therapeutics has signed a clinical collaboration with AstraZeneca and its Japan-based partner Daiichi Sankyo to evaluate ivonescimab in combination with the antibody-drug conjugate Datroway, also known as datopotamab deruxtecan, across multiple solid tumors including breast and lung cancers. The collaboration is expected to initially focus on a phase III study in first-line triple-negative breast cancer, expanding ivonescimab's development into a new tumor type. Under the agreement, each company will supply its respective drug, AstraZeneca or Daiichi will sponsor the planned studies, and the companies will share study costs while retaining development and commercial rights to their own therapies. The Datroway collaboration builds on the larger deal between AstraZeneca and Summit announced in the last week, under which AstraZeneca agreed to invest $2 billion in Summit to accelerate development of ivonescimab, with the companies also set to evaluate ivonescimab alongside AstraZeneca's investigational Claudin-18.2-targeted ADC sonesitatug vedotin, or Sone-Ve, in gastrointestinal cancers. An FDA filing is under review seeking approval for ivonescimab plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who had progressed following EGFR-TKI treatment, with a final decision expected by Nov. 14, 2026.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Capital
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Capital
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Capital
4568.JP · Technology · Positive Daiichi Sankyo's Datroway (datopotamab deruxtecan) will be evaluated in combination with ivonescimab across multiple solid tumors, including a phase III triple-negative breast cancer study
AZN.LSE · Technology · Positive AstraZeneca will co-sponsor and supply its Datroway ADC in a new phase III combination study with ivonescimab, expanding its oncology pipeline
FDA Expands Eli Lilly's Jaypirca to First-Line CLL/SLL Treatment
Eli Lilly announced that the FDA has expanded the label of its oral cancer drug Jaypirca, also known as pirtobrutinib, to include a new indication in chronic lymphocytic leukemia or small lymphocytic lymphoma. Jaypirca has been approved to treat adults with previously untreated CLL/SLL who do not have a known 17p deletion, allowing the drug to be used as a first-line treatment for eligible patients. The approval is supported by data from the phase III BRUIN CLL-313 study, which showed that Jaypirca reduced the risk of disease progression or death by 80% compared to chemoimmunotherapy. Before this latest approval, Jaypirca was already approved for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor, and for adults with relapsed or refractory mantle cell lymphoma following two lines of systemic therapy including a BTK inhibitor. Jaypirca is already generating meaningful sales for Lilly, with revenues rising 66% year over year to $357 million in the first half of 2026, though its sales remain relatively small compared with Lilly's much larger obesity and diabetes portfolio.
